Literature DB >> 32369341

Antimalarial Trioxolanes with Superior Drug-Like Properties and In Vivo Efficacy.

Brian R Blank1, Ryan L Gonciarz1, Poulami Talukder1, Jiri Gut2, Jennifer Legac2, Philip J Rosenthal2, Adam R Renslo1.   

Abstract

The emergence of artemisinin resistance, combined with certain suboptimal properties of ozonide agents arterolane and artefenomel, has necessitated the search for new drug candidates in the endoperoxide class. Our group has focused on trioxolane analogues with substitution patterns not previously explored. Here, we describe the enantioselective synthesis of analogues bearing a trans-3″ carbamate side chain and find these to be superior, both in vitro and in vivo, to the previously reported amides. We identified multiple analogues that surpass the oral efficacy of arterolane in the Plasmodium berghei model while exhibiting drug-like properties (logD, solubility, metabolic stability) similar or superior to next-generation clinical candidates like E209 and OZ609. While the preclinical assessment of new analogues is still underway, current data suggest the potential of this chemotype as a likely source of future drug candidates from the endoperoxide class.

Entities:  

Keywords:  antimalarials; endoperoxides; lead optimization; stereoselective synthesis; trioxolanes

Mesh:

Substances:

Year:  2020        PMID: 32369341      PMCID: PMC7363035          DOI: 10.1021/acsinfecdis.0c00064

Source DB:  PubMed          Journal:  ACS Infect Dis        ISSN: 2373-8227            Impact factor:   5.084


  17 in total

1.  Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).

Authors:  Yuxiang Dong; Xiaofang Wang; Sriraghavan Kamaraj; Vivek J Bulbule; Francis C K Chiu; Jacques Chollet; Manickam Dhanasekaran; Christopher D Hein; Petros Papastogiannidis; Julia Morizzi; David M Shackleford; Helena Barker; Eileen Ryan; Christian Scheurer; Yuanqing Tang; Qingjie Zhao; Lin Zhou; Karen L White; Heinrich Urwyler; William N Charman; Hugues Matile; Sergio Wittlin; Susan A Charman; Jonathan L Vennerstrom
Journal:  J Med Chem       Date:  2017-01-18       Impact factor: 7.446

2.  Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria.

Authors:  Susan A Charman; Sarah Arbe-Barnes; Ian C Bathurst; Reto Brun; Michael Campbell; William N Charman; Francis C K Chiu; Jacques Chollet; J Carl Craft; Darren J Creek; Yuxiang Dong; Hugues Matile; Melanie Maurer; Julia Morizzi; Tien Nguyen; Petros Papastogiannidis; Christian Scheurer; David M Shackleford; Kamaraj Sriraghavan; Lukas Stingelin; Yuanqing Tang; Heinrich Urwyler; Xiaofang Wang; Karen L White; Sergio Wittlin; Lin Zhou; Jonathan L Vennerstrom
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-07       Impact factor: 11.205

3.  Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study.

Authors:  Chanaki Amaratunga; Pharath Lim; Seila Suon; Sokunthea Sreng; Sivanna Mao; Chantha Sopha; Baramey Sam; Dalin Dek; Vorleak Try; Roberto Amato; Daniel Blessborn; Lijiang Song; Gregory S Tullo; Michael P Fay; Jennifer M Anderson; Joel Tarning; Rick M Fairhurst
Journal:  Lancet Infect Dis       Date:  2016-01-08       Impact factor: 25.071

4.  Efficient and stereocontrolled synthesis of 1,2,4-trioxolanes useful for ferrous iron-dependent drug delivery.

Authors:  Shaun D Fontaine; Antonio G DiPasquale; Adam R Renslo
Journal:  Org Lett       Date:  2014-10-21       Impact factor: 6.005

5.  Enantioselective Synthesis and in Vivo Evaluation of Regioisomeric Analogues of the Antimalarial Arterolane.

Authors:  Brian R Blank; Jiri Gut; Philip J Rosenthal; Adam R Renslo
Journal:  J Med Chem       Date:  2017-07-10       Impact factor: 7.446

6.  A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance.

Authors:  Paul M O'Neill; Richard K Amewu; Susan A Charman; Sunil Sabbani; Nina F Gnädig; Judith Straimer; David A Fidock; Emma R Shore; Natalie L Roberts; Michael H-L Wong; W David Hong; Chandrakala Pidathala; Chris Riley; Ben Murphy; Ghaith Aljayyoussi; Francisco Javier Gamo; Laura Sanz; Janneth Rodrigues; Carolina Gonzalez Cortes; Esperanza Herreros; Iñigo Angulo-Barturén; María Belén Jiménez-Díaz; Santiago Ferrer Bazaga; María Santos Martínez-Martínez; Brice Campo; Raman Sharma; Eileen Ryan; David M Shackleford; Simon Campbell; Dennis A Smith; Grennady Wirjanata; Rintis Noviyanti; Ric N Price; Jutta Marfurt; Michael J Palmer; Ian M Copple; Amy E Mercer; Andrea Ruecker; Michael J Delves; Robert E Sinden; Peter Siegl; Jill Davies; Rosemary Rochford; Clemens H M Kocken; Anne-Marie Zeeman; Gemma L Nixon; Giancarlo A Biagini; Stephen A Ward
Journal:  Nat Commun       Date:  2017-05-24       Impact factor: 14.919

7.  Plasmodium falciparum K13 Mutations Differentially Impact Ozonide Susceptibility and Parasite Fitness In Vitro.

Authors:  Judith Straimer; Nina F Gnädig; Barbara H Stokes; Michelle Ehrenberger; Audrey A Crane; David A Fidock
Journal:  mBio       Date:  2017-04-11       Impact factor: 7.867

8.  In vitro activity of anti-malarial ozonides against an artemisinin-resistant isolate.

Authors:  Fabian Baumgärtner; Joëlle Jourdan; Christian Scheurer; Benjamin Blasco; Brice Campo; Pascal Mäser; Sergio Wittlin
Journal:  Malar J       Date:  2017-01-25       Impact factor: 2.979

9.  Anti-malarial ozonides OZ439 and OZ609 tested at clinically relevant compound exposure parameters in a novel ring-stage survival assay.

Authors:  Annabelle Walz; Didier Leroy; Nicole Andenmatten; Pascal Mäser; Sergio Wittlin
Journal:  Malar J       Date:  2019-12-18       Impact factor: 2.979

10.  An in vitro toolbox to accelerate anti-malarial drug discovery and development.

Authors:  Susan A Charman; Alice Andreu; Helena Barker; Scott Blundell; Anna Campbell; Michael Campbell; Gong Chen; Francis C K Chiu; Elly Crighton; Kasiram Katneni; Julia Morizzi; Rahul Patil; Thao Pham; Eileen Ryan; Jessica Saunders; David M Shackleford; Karen L White; Lisa Almond; Maurice Dickins; Dennis A Smith; Joerg J Moehrle; Jeremy N Burrows; Nada Abla
Journal:  Malar J       Date:  2020-01-02       Impact factor: 2.979

View more
  4 in total

Review 1.  Natural Products That Changed Society.

Authors:  Søren Brøgger Christensen
Journal:  Biomedicines       Date:  2021-04-26

2.  Ferrous iron-activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors.

Authors:  Honglin Jiang; Ryan K Muir; Ryan L Gonciarz; Adam B Olshen; Iwei Yeh; Byron C Hann; Ning Zhao; Yung-Hua Wang; Spencer C Behr; James E Korkola; Michael J Evans; Eric A Collisson; Adam R Renslo
Journal:  J Exp Med       Date:  2022-03-09       Impact factor: 17.579

3.  Expanded scope of Griesbaum co-ozonolysis for the preparation of structurally diverse sensors of ferrous iron.

Authors:  Jun Chen; Ryan L Gonciarz; Adam R Renslo
Journal:  RSC Adv       Date:  2021-10-22       Impact factor: 3.361

4.  Enantioselective Synthesis and Profiling of Potent, Nonlinear Analogues of Antimalarial Tetraoxanes E209 and N205.

Authors:  Christopher M Woodley; Gemma L Nixon; Nicoletta Basilico; Silvia Parapini; Weiqian David Hong; Stephen A Ward; Giancarlo A Biagini; Suet C Leung; Donatella Taramelli; Keiko Onuma; Takashi Hasebe; Paul M O'Neill
Journal:  ACS Med Chem Lett       Date:  2021-06-24       Impact factor: 4.632

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.